OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Discovery is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
AI-Supported Mammography “Safe,” Cuts Workload	5688
HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion	578
Mutation-Driven Alveolar Cell Reprogramming Dictates Lung Cancer Progression	360
Succinyl-CoA and Cobalamin Are Biomarkers That Improve Anal Cancer Screening	307
Human Tumor Cells Display an Oncogene-like Addiction to Aneuploidy	257
Q&A: Philip Greenberg on T Cells, IO's Future	226
Structure of the Tumor Stroma Predicts Invasive Breast Cancer Relapse	214
Shattered Chromosomes Undergo Mitotic Tethering during Chromothripsis	196
PARADIGM Identifies Associations between Drugs, the Microbiome, and Mortality	195
Air Pollution Promotes Oncogenic Expansion of Mutant Lung Progenitor Cells	188
Transposable Element Signatures Define Stages of T-cell Exhaustion	188
Probing Clonal Hematopoiesis in Liquid Biopsy	186
Collagen Receptor Implicated in Immune Exclusion	180
Low-Glycemic Diets Restrict Tumor Growth through Altered Lipid Metabolism	179
Exome Sequencing IDs Hidden Disease Variants	173
IL7 Genetic Variation Predicts Immune-Related Adverse Events	170
Drafting a Blueprint for European Cancer Research	166
RAS Drives Malignancy through Altered Stem Cell/Microenvironment Cross-talk	164
Dendritic Cell Circadian Rhythm Governs the Antitumor Immune Response	153
COVID-19 Reshapes Cancer Clinical Research	149
Colorectal Cancer Screening to Start at 45	148
Myeloid Cells Counter Immune Suppression	148
Blood Cancers Diminish Response to COVID-19 Vaccine	145
Durable Responses with Vemurafenib plus Rituximab in Hairy-Cell Leukemia	143
Cytosolic Phospholipase A2 determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response	137

Mouse Models Provide Insight into Factors Affecting BiTE Efficacy	137
Highlighted research articles	134
Proteostasis Network Modulation Promotes Resistance to KRAS Inhibitors	130
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?	126
REFLECTions on Combination Therapies Empowered by Data Sharing	126
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma	124
Highlighted research articles	123
Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer	123
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	122
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers	120
Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta	119
Infigratinib Approved for Cholangiocarcinoma	119
Correction: Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer	117
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC	117
PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway	117
An NK-cell Therapy for CD30+ Lymphomas	116
Intrinsic properties of the lymph node render it immunologically susceptible to metastasis	115
CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma	115
Lymph Node Metastasis Induces Immune Tolerance and Distant Metastasis	115
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy	113
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression	111
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression	111
Trispecifics Improve Immune-Cell Engagement	109
A Guide to Extrachromosomal DNA: Cancer’s Dynamic Circular Genome	109
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors	109
GIST: Molecular Profiling Suggests 2nd Therapy	108
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	108
The 3D Revolution in Cancer Discovery	108
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma	102
Chronic Inflammation Drives TP53-Mutant Leukemic Evolution	100
Presurgery Plus Postsurgery Immunotherapy Ups Survival in NSCLC	100
In This Issue	100
Multicellular Spatial Organization Determines Immunotherapy Response	100
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors	98
Amgen Deal Nets Potential Cancer Therapies	97
Tumor-Derived Extracellular Vesicles and Particles Inhibit Liver Function	96
The Proteasome Regulator PSME4 Modulates Antitumor Immunity	96
Intestinal Microbiome Inhibits CD8+ T Cells via the Calcineurin–NFAT Axis	96
FMRP Depletion Reprograms an Immunosuppressive Microenvironment	95
New Strategy May Thwart Glioblastoma Resistance	92
Hyperactivation of Oncogenic Pathways Hinders Cancer Cell Survival	91
TILs Outperform Ipilimumab in Melanoma	91
Akk Abundance Alters Survival in Patients with NSCLC on ICIs	90
Lymph Node–Specific IFNγ Levels Affect CD8+ T-cell Priming against Tumors	90
What's Next for Sotorasib in NSCLC?	89
Revumenib Is Safe and Efficacious, but MEN1 Mutations Mediate Resistance	89
Aged Lungs Enable Metastatic Outgrowth of Dormant Melanoma Cells	89
Biomarker Testing Falls Short in NSCLC	87
In This Issue	87
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy	85

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	85
Oncogenic KRAS-Dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth	84
Noninvasive and Multicancer Biomarkers: The Promise of LINE-1 Retrotransposons	83
Bridging the Gap between Diseases of the Stomach and Lower Esophagus	80
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology	80
Atypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53	80